BIO Asia–Taiwan 2025 亞洲生技大會

• New technologies are accelerating the global launch of new drugs

• Winning strategies in bringing new drugs to global markets.

This exciting session will feature insights from Dr. John Tsai, Former President of Global Product Development & Chief Medical Officer at Novartis; serial entrepreneur Dr. Luk Vandenberghe of Harvard Medical School, representing his trailblazing genetic therapy company AKOUOS; Dr. Feng Ren, Co-CEO & CSO of AI drug discovery pioneer Insilico Medicine; and Dr. Gur Roshmalb, partner at leading Israeli investment fund aMoon. A must-attend event for drug development executives based in the Asia-Pacific or seeking to tap into Asian markets from abroad, this session gathers the expertise of industry veterans regarding novel technologies such as AI, gene therapy, and cell therapy, to illuminate a clear path for bringing new therapies to global markets. Register now at BIO Asia—Taiwan 2023 to secure admission and early bird rates!